Fertility preservation in patients receiving cyclophosphamide therapy for renal disease

Radha Gajjar, Steven Miller, Kevin E. Meyers, Jill P. Ginsberg

Research output: Contribution to journalArticle

Abstract

Cyclophosphamide continues to have an important role in the treatment of renal disease, including nephrotic syndrome and lupus nephritis, despite known complications of gonadotoxicity and potential infertility in both male and female patients. It is important that the physician recommending this therapy mitigates the effect of the drug on fertility by adhering to recommendations on dosing limits and offering fertility-preserving strategies. In addition to well-established methods, such as sperm banking and embryo cryopreservation, advances in reproductive technology have yielded strategies such as oocyte cryopreservation, resulting in more fertility-preserving options for the pediatric patient. Despite these advances, there continues to be a significant barrier to referral and access to sperm banks and fertility specialists. These issues are further complicated by ethical issues associated with the treatment of pediatric patients. In this review we explore the development of recommended dosing limits and include a discussion of the available fertility-preserving methods, strategies for increasing access to fertility specialists, and the ethical considerations facing the pediatric healthcare provider.

Original languageEnglish (US)
Pages (from-to)1099-1106
Number of pages8
JournalPediatric Nephrology
Volume30
Issue number7
DOIs
StatePublished - Jul 29 2015

Fingerprint

Fertility Preservation
Cyclophosphamide
Fertility
Kidney
Cryopreservation
Pediatrics
Sperm Banks
Fertility Agents
Reproductive Techniques
Therapeutics
Lupus Nephritis
Nephrotic Syndrome
Ethics
Health Personnel
Infertility
Oocytes
Spermatozoa
Referral and Consultation
Embryonic Structures
Physicians

Keywords

  • Fertility preservation
  • Gonadotoxicity
  • Intracytoplasmic sperm injection
  • Oocyte cryopreservation
  • Sperm banking

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Fertility preservation in patients receiving cyclophosphamide therapy for renal disease. / Gajjar, Radha; Miller, Steven; Meyers, Kevin E.; Ginsberg, Jill P.

In: Pediatric Nephrology, Vol. 30, No. 7, 29.07.2015, p. 1099-1106.

Research output: Contribution to journalArticle

Gajjar, Radha ; Miller, Steven ; Meyers, Kevin E. ; Ginsberg, Jill P. / Fertility preservation in patients receiving cyclophosphamide therapy for renal disease. In: Pediatric Nephrology. 2015 ; Vol. 30, No. 7. pp. 1099-1106.
@article{79d4da2d921f42c6bc5f3cf0372f44a1,
title = "Fertility preservation in patients receiving cyclophosphamide therapy for renal disease",
abstract = "Cyclophosphamide continues to have an important role in the treatment of renal disease, including nephrotic syndrome and lupus nephritis, despite known complications of gonadotoxicity and potential infertility in both male and female patients. It is important that the physician recommending this therapy mitigates the effect of the drug on fertility by adhering to recommendations on dosing limits and offering fertility-preserving strategies. In addition to well-established methods, such as sperm banking and embryo cryopreservation, advances in reproductive technology have yielded strategies such as oocyte cryopreservation, resulting in more fertility-preserving options for the pediatric patient. Despite these advances, there continues to be a significant barrier to referral and access to sperm banks and fertility specialists. These issues are further complicated by ethical issues associated with the treatment of pediatric patients. In this review we explore the development of recommended dosing limits and include a discussion of the available fertility-preserving methods, strategies for increasing access to fertility specialists, and the ethical considerations facing the pediatric healthcare provider.",
keywords = "Fertility preservation, Gonadotoxicity, Intracytoplasmic sperm injection, Oocyte cryopreservation, Sperm banking",
author = "Radha Gajjar and Steven Miller and Meyers, {Kevin E.} and Ginsberg, {Jill P.}",
year = "2015",
month = "7",
day = "29",
doi = "10.1007/s00467-014-2897-1",
language = "English (US)",
volume = "30",
pages = "1099--1106",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Fertility preservation in patients receiving cyclophosphamide therapy for renal disease

AU - Gajjar, Radha

AU - Miller, Steven

AU - Meyers, Kevin E.

AU - Ginsberg, Jill P.

PY - 2015/7/29

Y1 - 2015/7/29

N2 - Cyclophosphamide continues to have an important role in the treatment of renal disease, including nephrotic syndrome and lupus nephritis, despite known complications of gonadotoxicity and potential infertility in both male and female patients. It is important that the physician recommending this therapy mitigates the effect of the drug on fertility by adhering to recommendations on dosing limits and offering fertility-preserving strategies. In addition to well-established methods, such as sperm banking and embryo cryopreservation, advances in reproductive technology have yielded strategies such as oocyte cryopreservation, resulting in more fertility-preserving options for the pediatric patient. Despite these advances, there continues to be a significant barrier to referral and access to sperm banks and fertility specialists. These issues are further complicated by ethical issues associated with the treatment of pediatric patients. In this review we explore the development of recommended dosing limits and include a discussion of the available fertility-preserving methods, strategies for increasing access to fertility specialists, and the ethical considerations facing the pediatric healthcare provider.

AB - Cyclophosphamide continues to have an important role in the treatment of renal disease, including nephrotic syndrome and lupus nephritis, despite known complications of gonadotoxicity and potential infertility in both male and female patients. It is important that the physician recommending this therapy mitigates the effect of the drug on fertility by adhering to recommendations on dosing limits and offering fertility-preserving strategies. In addition to well-established methods, such as sperm banking and embryo cryopreservation, advances in reproductive technology have yielded strategies such as oocyte cryopreservation, resulting in more fertility-preserving options for the pediatric patient. Despite these advances, there continues to be a significant barrier to referral and access to sperm banks and fertility specialists. These issues are further complicated by ethical issues associated with the treatment of pediatric patients. In this review we explore the development of recommended dosing limits and include a discussion of the available fertility-preserving methods, strategies for increasing access to fertility specialists, and the ethical considerations facing the pediatric healthcare provider.

KW - Fertility preservation

KW - Gonadotoxicity

KW - Intracytoplasmic sperm injection

KW - Oocyte cryopreservation

KW - Sperm banking

UR - http://www.scopus.com/inward/record.url?scp=84930226109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930226109&partnerID=8YFLogxK

U2 - 10.1007/s00467-014-2897-1

DO - 10.1007/s00467-014-2897-1

M3 - Article

C2 - 25190492

AN - SCOPUS:84930226109

VL - 30

SP - 1099

EP - 1106

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 7

ER -